Pulmonary arterial hypertension

E-Communication Session
Chairs: M. Kneussl (Vienna, Austria), A. Vonk Noordegraaf (Amsterdam, Netherlands)

Haemoptysis in pulmonary arterial hypertension (PAH): a life-threatening complication X. Jais, L. Savale, O. Sitbon, D. Montani, L. Price, J. Le Pavec, B. Sztrymf, C. Tcherakian, M. Humbert, G. Simonneau (Clamart, France)
The impact of pulmonary parameters on non-invasive measurement of cardiac output by the inert gas rebreathing method J. Saur, F. Trinkmann, C. Doesch, T. Papavassiliu, A. Scherhag, S. O. Schoenberg, M. Borggrefe, J. J. Kaden (Mannheim, Germany)
Hemodynamic predictors of survival in scleroderma related pulmonary hypertension: a single center study A. Campo Ezquibela, S. K. Mathai, R. E. Girgis, A. L. Zaiman, L. Hummers, F. Wigley, P. M. Hassoun (Pamplona, Spain; Baltimore, United States Of America)
Sympathetic nervous system activation is an independent prognostic factor of clinical deterioration in pulmonary arterial hypertensive patients A. Ciarka, V. Phoung, S. Huez, J. L. Vachiery, R. Naeije, P. van de Borne (Brussels, Belgium)
Does sympathovagal imbalance predict clinical outcome in patients with PAH? M. Can, I. Tanboga, H. Tokgoz, E. Turkyilmaz, T. Akgun, F. Koca, A. Ozkan, M. Saglam, O. Ozveren, C. Kaymaz (Istanbul, MUS, Batman, Kütahya, Turkey)
Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH R. J. Oudiz, B. Brundage, N. Galié, G. Simonneau, R. B. Barst, A. Elion-Mboussa, A. Beardsworth, H. A. Ghofrani (Torrance, Bend, New York City, Indianapolis, United States Of America; Bologna, Italy; Clamart, France; Giessen, Germany)
Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension J. Pepke-Zaba, A. Beardsworth, M. Chan, M. Angalakuditi (Cambridge, London, United Kingdom; Toronto, Canada; Indianapolis, United States Of America)
Subcutaneous treprostinil: a new therapeutic approach for idiopathic paediatric pulmonary hypertension M. Levy, F. Bajolle, S. Cohen, D. Bonnet (Paris, France)
Pulmonary arterial hypertension in end-stage idiopathic pulmonary fibrosis: a hypothetic role for viral infections F. Lunardi, B. Nordio, E. Balestro, M. Loy, G. Marulli, M. Saetta, F. Rea, F. Calabrese (Padua, Italy)
Pulmonary hypertension in systemic lupus erythematosus – a retrospective analysis R. Lee, R. Martin, G. Coghlan, D. D‘Cruz (London, United Kingdom)
Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-centre study R. Sadushi-Kolici, D. Bonderman, N. Skoro-Sajer, J. Glatz, M. Kneussl, I. Lang (Vienna, Austria)
Stroke volume and heart rate response to exercise differ in pulmonary arterial hypertension and left heart failure H. Groepenhoff, N. Westerhof, A. Boonstra, P. E. Postmus, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
The value of high-resolution computed tomography of lungs (HRCT) in idiopathic pulmonary arterial hypertension (IPAH) M. Szturmowicz, A. Kacprzak, B. Burakowska, M. Kurzyna, A. Fijalkowska, M. Florczyk, J. Zylkowska, I. Bestry, A. Torbicki (Warsaw, Poland)
Estimation of pulmonary distensibility via non-invasive cardiopulmonary exercise testing: a potential guide to normal physiology P. Argiento, N. Chesler, M. A. Witters, P. Unger, M. D‘Alto, E. Bossone, R. Naeije (Naples, Milano, Italy; Madison, United States Of America; Brussels, Belgium)
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction O. Minai, H. Chen, Parambil, Blair, Davila, D. Strootman, M. Wade, K. Rollins, Dweik (Cleveland, San Francisco, Research Triangle Park, United States Of America)
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension K. Kemp, O. Sitbon, X. Jaïs, L. Savale, M. Humbert, G. Simonneau (Clamart, France)
Epidemiology of pulmonary hypertension. Preliminary results of the Spanish pulmonary hypertension registry A. Roman, P. Escribano, J. A. Barberà, C. Jimenez, I. Blanco, M. López, F. García, J. Gaudo, E. Sala, P. Morales (Barcelona, Madrid, Sevilla, Palma de Mallorca, Valencia, Spain)
Unexpected high prevalence of left ventricular cardiopathy in patients with COPD K. Portillo, X. Freixa, C. Paré, J. García-Aymerich, F. P. Gomez, M. Benet, J. Roca, J. M. Antó, J. A. Barberá (Barcelona, Spain)
Pulmonary diffusion variables in Andeans and Himalayans H. Guénard, C. De Bisschop, G. Leurquin, V. Faoro, J. B. Martinot, R. Naeije (Bordeaux, Poitiers, France; Brussels, Namur, Belgium)
The role of NO pathway in pathogenesis of hypoxic pulmonary vasoconstriction in healthy volunteers during acclimatisation to 3,800 m A. Adashev, A. Akunov, J. Isakova, M. Wilkins, B. Kojonazarov (Bishkek, Kyrgyzstan; London, United Kingdom)